Literature DB >> 23789905

Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplation.

Thomas Clozel, Benedicte Deau, Claire Benet, Patricia Franchi, Marie Robin, Isabelle Madelaine, Catherine Thieblemont, Eric de Kerviler, Josette Brière, Pauline Brice.   

Abstract

Entities:  

Keywords:  Hodgkin lymphoma; drugs; high dose therapy

Mesh：

Substances：

Year:  2013        PMID： 23789905     DOI： 10.1111/bjh.12428

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.

Authors:  C Y Cheah; D Chihara; S Horowitz; A Sevin; Y Oki; S Zhou; N H Fowler; J E Romaguera; F Turturro; F B Hagemeister; L E Fayad; M Wang; S S Neelapu; L J Nastoupil; J R Westin; M A Rodriguez; F Samaniego; P Anderlini; Y Nieto; M A Fanale
Journal:  Ann Oncol       Date:  2016-04-18       Impact factor: 32.976

Review 2.  Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma.

Authors:  Liana Nikolaenko; Robert Chen; Alex F Herrera
Journal:  Ther Adv Hematol       Date:  2017-08-29

3.  New agents in relapsed/refractory Hodgkin's lymphoma.

Authors:  Irene Biasoli; Nelson Spector
Journal:  Rev Bras Hematol Hemoter       Date:  2017-05-28

Review 4.  Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.

Authors:  David A Bond; Lapo Alinari
Journal:  J Blood Med       Date:  2017-05-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.